The two firms, which have a long history of working together, said
on Monday that Aspen would pay 180 million pounds for the products
Ultiva, Nimbex, Tracrium, Mivacron and Anectinein, plus up to 100
million pounds in milestone payments.
GSK, which had already sold the U.S. and Canadian rights to the
drugs, earned around 35 million pounds from the anaesthetics in the
first half of 2016.
Aspen is also acquiring rights to the remaining GSK thrombosis drug
portfolio, while the two companies are ending a broader
collaboration in sub-Saharan Africa.
The South African group bought most of the thrombosis drug rights in
2013, but GSK had retained certain territories, including China,
India and Pakistan.
($1 = 0.7532 pounds)
[to top of second column]
(Reporting by Ben Hirschler; Editing by Alexander Smith)
[© 2016 Thomson Reuters. All rights
Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.